A Study to Evaluate the Efficacy of Alfuzosin in Clearance of Distal Ureteric Calculi

Introduction: Urinary stone disease is a major health problemnot only because of high prevalence but also because it affectsthe young and productive population of the society. The currentstudy was performed to assess and compare the expulsiveeffects of orally administered Afluzosin as medically expulsivetherapy for distal ureteral calculi less than 8 mm in diameterwhen administered upto 21 days after the first painfulmanifestation.Materials and Methods: A total of 60 patients with distalureteric calculi were enrolled in the study and were divided intwo groups. The control group comprised of 30 patients withdistal ureteric calculi who were given Cap. Becosule (Vitamin BComplex) (Placebo) once a day for clearance of ureteric calculiwith plenty of fluids and analgesics as and when required. Thestudy group comprised of 30 patients with distal ureteric calculiwho were given Tab. Alfuzosin hydrochloride 10 mg once aday for clearance of ureteric calculi with plenty of fluids andanalgesics as and when required. The outcome was measuredin terms of passage of calculi, no. of days taken for passage ofcalculi and no. of analgesic tablets consumed until passage.The statistical analysis was done using chi-square test forproportions and Independent samples "t" test for comparingmeans between the two groups and a p value less than 0.05indicated statistically significant difference.Results: In study group, stone was passed within 21 days ofstudy period in 26 (86.7%) subjects whereas in control group, itcould pass in only 14 (46.7%) patients thus showing asignificant statistical difference between two groups (p=0.001).Mean analgesic intake was 6.63±1.38 tablets in study groupand 8.63±3.26 tablets in control group, thus showing that themean analgesic intake was significantly high in control groupas compared to study group (p=0.009).Conclusion: In our study Patients in Alfuzosin groupdemonstrated a higher incidence of spontaneous stonepassage, more rapid stone passage and a decreased need foranalgesic. This selective α1 blocker should therefore beincluded in different schedules used worldwide, when aconservative approach to this very common urological problemis considered.